Trials / Completed
CompletedNCT00380887
Study Comparing Four New Formulations for Premarin in Healthy Postmenopausal Women
An Open-Label, Single-Dose, Randomized, 4-Period, Partial Crossover Bioequivalence/Bioavailability Study Among Four New Formulations of Premarin 0.45 mg/Medroxyprogesterone Acetate (MPA) 1.5 mg Compared With a Reference Formulation of Premarin/MPA (Prempro) 0.45 mg/1.5 mg in Healthy Postmenopausal Women
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (planned)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 35 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine bioequivalence and bioavailability of four different Premarin/MPA test formulations versus the current formulation for Prempro.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Premarin |
Timeline
- Start date
- 2005-06-01
- First posted
- 2006-09-27
- Last updated
- 2006-09-27
Source: ClinicalTrials.gov record NCT00380887. Inclusion in this directory is not an endorsement.